Real-World Experience of Tixagevimab–cilgavimab in High-risk, Immunocompromised Coronavirus Disease 2019 Patients

Abstract

Abstract Objectives: We aimed to examine the effectiveness of tixagevimab–cilgavimab (Evusheld) during the coronavirus disease 2019 (COVID-19) B.1.1.529, BA.4, and BA.5 surges among high-risk, immunocompromised patients. Methods: We performed a cohort analysis of high-risk, immunocompromised patients who were referred for tixagevimab–cilgavimab treatment from January 14, 2022, to August 1, 2022. A descriptive analysis was performed of all patients who met the study inclusion criteria. Primary outcome was the development of COVID-19 infection. Secondary outcome was COVID-19-related mortality. Results: There were 620 patients (median age: 65 years) who met inclusion criteria. Patients were followed for a median of 166 days (range: 111–196 days) after administration of tixagevimab–cilgavimab. The primary outcome was met in 33 (5.3%) of patients and there were zero deaths attributable to COVID-19. No adverse events from tixagevimab–cilgavimab were reported. Conclusions: Tixagevimab–cilgavimab may be effective in preventing COVID-19 infections in high-risk, immunocompromised individuals.